ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO679

Role of Reticulocyte-Hemoglobin in Predicting Hemoglobin Changes in Patients With Anemia Undergoing Maintenance Hemodialysis

Session Information

  • Anemia and Iron Metabolism
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism


  • Kim, Beong Woo, Inje University College of Medicine, Busan, Korea (the Republic of)
  • Kim, Taehee, Inje University College of Medicine, Busan, Korea (the Republic of)
  • Kim, Yeong Hoon, Inje University College of Medicine, Busan, Korea (the Republic of)
  • Kim, Yunmi, Inje University College of Medicine, Busan, Korea (the Republic of)
  • Huh, Hyuk, Inje University College of Medicine, Busan, Korea (the Republic of)

It has been suggested that reticulocyte-hemoglobin (Ret-Hb) may be useful as a tool for managing iron deficiency anemia in hemodialysis (HD) patients on erythropoiesis-stimulating agents (ESA). The purpose of this study was to determine the correlation between Ret-Hb and traditional predictors of iron deficiency anemia, and to compare their function as predictors of anemia.


From July 2021 to October 2022, hemoglobin changes for 3 months (ΔHb), Ret-Hb, Transferrin saturation (TSAT), and ferritin were measured every quarter in patients receiving regular HD for more than 90 days. The correlation between Ret-Hb, TSAT, and ferritin was confirmed through linear regression analysis. Subsequently, Ret-Hb, TSAT and ferritin were analyzed for correlation with ΔHb to compare their potential as predictors of anemia. Patients with ESA hyporesponsiveness, bleeding, infection, hematologic disease and malignancy were excluded from the study.


A total of 72 patients were included in the study, the mean age was 63.40 ± 7.79 years, 33 men (54.15%), and 61 patients (84.7%) receiving iron therapy. Ret-Hb showed a clear positive correlation with TSAT (r = 0.397, p < 0.001), but not with ferritin (r = 0.039, p = 0.746). Regarding the association with ΔHb, only Ret-Hb had a statistically significant negative correlation (r = -0.274, p = 0.021), and TSAT (r = 0.015, p = 0.904) and ferritin (r = -0.184, p = 0.125) did not show significant correlation.


Ret-Hb showed a significant correlation with TSAT, it was shown that it can be used as an auxiliary indicator to evaluate iron deficiency. In addition, since it showed a significant correlation with hemoglobin changes, Ret-Hb may have an additional role in evaluating the response to anemia treatment in patients undergoing hemodialysis in the future.